Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients
| Autor: | Hassan Abolghasemi, MD, Yunes Panahi, PhD, Minoo. Ahmadinejad, MD, Gholamreza Toogeh, MD, Mehran Karimi, MD, Aziz Eghbali, MD, Nargess Bigom Mirbehbahani, MD, Bighan Keikhaei Dehdezi, MD, Zahra Badiee, MD, Hamid Hoorfar, MD, Peyman Eshghi, MD, Nader Maghsoudi, PhD, Amirhossein Sahebkar, PhD, Mohammad Gholami- Fesharaki, PhD |
|---|---|
| Jazyk: | English<br />Korean |
| Rok vydání: | 2018 |
| Předmět: | |
| Zdroj: | Journal of Pharmacopuncture, Vol 21, Iss 2, Pp 76-81 (2018) |
| Druh dokumentu: | article |
| ISSN: | 2093-6966 2234-6856 |
| DOI: | 10.3831/KPI.2018.21.009 |
| Popis: | Objective: This study compared the safety and efficacy of Safacto® versus xyntha® in patients with severe hemophilia A. Methods: Thirty-three male patients with severe hemophilia A were randomly divided into two groups. Seventeen patients received Safacto® and 16 patients received Xyntha® for four consecutive times. The dosage of FVIII was 40-50 IU/kg for each injection. Plasma level of FVIII activity was evaluated before every injection, 15 minutes after the injection and one month after the start of the trial. The rate of factor VIII activity, pain and joint motion were also assessed before and after the treatment. Results: Plasma level of FVIII clotting activity in Safacto® and Xyntha® were 1.96±0.5 IU/dl and 1.63±0.5 IU/dl and increased to 88.84±25.2 IU/dl and 100.09±17.8 IU/ dl, respectively (P |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|